• Subscribe
  • About us
  • Advertise with us

NeuroSens

Menu

Skip to content
  • Home
  • Neurology
  • Psychiatry

Topic: MS

MS Sequencing: Part 4 – What is the treatment plan?

April 19, 2017  

FDA approves ocrelizumab in RRMS, PPMS

March 30, 2017  

Neurologists cautious about patient e-contact: survey

March 15, 2017  

Daclizumab approved in Canada for relapsing MS

March 3, 2017  

MS Sequencing: Part 3 – Evaluating treatment response

February 16, 2017  

NEUROSOUND: CHARCOT 2016 HIGHLIGHTS

January 25, 2017  

MS Sequencing: Part 2 – Treatment initiation

January 12, 2017  

Sun avoidance – more harm than good?

December 16, 2016  

MS Sequencing: Part 1 – Mechanism of action of DMTs

November 3, 2016  

ECTRIMS 2016 SLIDE DECK

October 24, 2016  
Previous
27
28
29
30
31
Next

Browse by Topic

  • MS (442)
  • EAN 2026 (2)
  • CLINICAL CASES (21)
  • AAN 2026 (3)
  • ACTRIMS Forum 2026 (4)
  • EPILEPSY (38)
  • AES 2025 (1)
  • BIOMARKERS IN MS (61)
  • ECTRIMS 2025 (7)
  • Library (18)
  • EAN 2025 (2)
  • AAN 2025 (5)
  • ACTRIMS 2025 (6)
  • AES 2024 (1)
  • ECTRIMS 2024 (6)
  • EAN 2024 (3)
  • AD (85)
  • AAN 2024 (5)
  • ACTRIMS Forum 2024 (2)
  • PD (77)
  • COVID-19 (58)
  • MIGRAINE (25)
  • DEPRESSION (36)
  • STROKE (22)
  • SCHIZOPHRENIA (25)
  • DEMENTIA (10)
  • SLEEP (2)
  • PAIN (3)
  • BPD (4)
  • ALS (1)

Popular Posts

  • Anti-CD20 therapy in MS: comparing efficacy and safety posted on July 21, 2026
  • Highlights of EAN 2026 – Part 1 posted on June 30, 2026
  • Proton pump inhibitors linked to neurological conditions posted on November 29, 2019
Copyright 2026 Lind Publishing Inc All rights reserved. Developed by Integration New Media, INC. (INM)
Contact Us Terms and Conditions